Om

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases and conditions linked to muscle decline, respiratory complications, and vision loss. Biophytis S.A. centers its portfolio on drug candidates designed to slow degenerative processes and improve functional outcomes, with programs spanning obesity-related muscle impairment, sarcopenia, Duchenne muscular dystrophy, COVID-19-related respiratory support, and age-related macular degeneration. The company’s work is aimed at addressing unmet medical needs in areas where aging and chronic degeneration significantly affect patient mobility, independence, and quality of life. Headquartered in Paris, France, Biophytis S.A. operates as a specialized player in the biotechnology market, combining clinical development expertise with a focus on therapies that target complex age-associated conditions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BIOPHYTIS MED ENDAVU: Køb Biophytis ($ALBPS) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Biophytis, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.